Annals of Medicine and Surgery · Oct 13, 2026
Comparative efficacy and safety of lorundrostat and baxdrostat in uncontrolled hypertension: a placebo-anchored indirect treatment comparison using the Bucher method
By Yousif MYE, Mohammed AHA, Mohammed Zaki MAM et al.
Background: Aldosterone synthase inhibitors are an emerging class that suppresses aldosterone biosynthesis via CYP11B2 inhibition, offering a mechanistically distinct alternative to mineralocorticoid receptor antagonists. Lorundrostat and baxdrostat have each demonstrated significant systolic blood pressure (SBP) reductions in randomized, placebo-controlled trials (RCTs), but no head-to-head trial has been conducted. Methods: We conducted a placebo-anchored adjusted indirect treatment comparison using the Bucher method within a star-shaped evidence network. The primary efficacy outcome was change in SBP. Safety outcomes were serious adverse events and hyperkalemia. Dose-specific and pooled analyses used a common-effects model with a shared placebo comparator. Results: Five placebo-controlled RCTs ( N = 2599) were included. Both agents significantly reduced SBP at all evaluated doses (all P < 0.0001): lorundrostat −7.87 mmHg at 50 mg and −6.66 mmHg at 100 mg; baxdrostat −8.50 mmHg at 1 mg and −10.22 mmHg at 2 mg. The lower-dose pair was statistically equivalent (lorundrostat 50 mg vs. baxdrostat 1 mg: mean difference (MD), +0.63 mmHg; P = 0.645); baxdrostat 2 mg produced a modest but significant advantage over lorundrostat 100 mg (MD, +3.56 mmHg; P = 0.043). Pooled SBP reductions were −7.64 mmHg and −9.36 mmHg for lorundrostat and baxdrostat, respectively; the pooled indirect comparison was not significant ( P = 0.163). Neither agent increased SAE risk versus placebo. Both agents markedly increased hyperkalemia risk (lorundrostat pooled risk ratio (RR), 8.16; baxdrostat pooled RR, 15.12); the between-drug comparison was not significant. I2 was 0% for SBP and hyperkalemia. Conclusions: Lorundrostat and baxdrostat show broadly comparable antihypertensive efficacy in uncontrolled hypertension; baxdrostat 2 mg produces a modest but statistically significant additional SBP reduction compared with lorundrostat 100 mg in a dose-level indirect comparison. Both agents markedly increase the risk of hyperkalemia versus placebo. Direct head-to-head trials are required to definitively establish comparative efficacy and safety.
doi.org/10.1097/ms9.0000000000005743Open accessPubMed 43017662Interventions